Scinovex
articleTop 1% cited

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

Arthritis & Rheumatism · 1993 · Vol. 36(12) · pp. 1681–1690
Michael J. ElliottRavinder N. MainiMarc FeldmannA. Long-FoxP. CharlesPeter D. KatsikisFionula M. BrennanJean WalkerHanny BijlJohn GhrayebJames N. Woody

Abstract

Treatment with anti-TNF alpha was safe and well tolerated and resulted in significant clinical and laboratory improvements. These preliminary results support the hypothesis that TNF alpha is an important regulator in RA, and suggest that it may be a useful new therapeutic target in this disease.

Rheumatoid Arthritis Research and TherapiesMonoclonal and Polyclonal Antibodies ResearchAutoimmune and Inflammatory Disorders ResearchMedicineRheumatoid arthritisTumor necrosis factor alphaInternal medicineMonoclonal antibodyGastroenterologyLiterMonoclonalAdverse effectArthritis

MeSH terms

AdultAgedAntibodies, MonoclonalArthritis, RheumatoidChimeraDose-Response Relationship, ImmunologicFemaleHumansImmunotherapyMaleMiddle AgedTumor Necrosis Factor-alphaCytokines
Citations
1,035
FWCI
54.15
field-weighted impact
References
42
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.